Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial
Version of Record online: 23 AUG 2012
© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry
Journal of Neurochemistry
Volume 123, Issue 2, pages 217–225, October 2012
How to Cite
J. Neurochem. (2012) 123, 217–225.
- Issue online: 1 OCT 2012
- Version of Record online: 23 AUG 2012
- Accepted manuscript online: 28 JUL 2012 09:45AM EST
- Manuscript Accepted: 24 JUL 2012
- Manuscript Revised: 23 JUL 2012
- Manuscript Received: 21 MAY 2012
- Neurovascular Research Laboratory
- Spanish stroke research. Grant Numbers: RENEVAS, RD06/0026/0010
- European Stroke Network. Grant Numbers: EUSTROKE 7FP Health F2-08-202213, PI080481, EC07/90195, CP09/00265, FI 10/00508
- Carlos III Health Institute
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|jnc7891-sup-0001-FigureS1.tif||image/tif||11887K||Figure S1. Stratified analysis of citicoline effect on infarct volume reduction by permanent or temporary occlusion model [25.4% (17.6%, 33.3%) vs. 30.2% (15.3%, 45.1%)] (S1); low dose (<250 mg) vs. high dose (>250 mg) [27.4% (14.6%, 40.2% vs. 27.4% (18.2%, 36.6%)] and single vs. multiple doses [22.6% (14.1%, 31.1%) vs. 31.1% (18.2%, 36.6%); p<0.05]. Columns represent mean effect size in % and vertical lines represent standard error of mean (SEM).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.